Cardiex Limited (ASX: CDX) has successfully raised AU$3.25 million through the placement of 36,111,112 shares at AU$0.09 per share, representing a 9.1% discount to the last closing price. Participants in the placement will receive one free attaching listed option for each share, exercisable at AU$0.20 and expiring on 30 November 2025. Supported by institutional and sophisticated investors, including directors and C2 Ventures Pty Limited (subject to shareholder approval), funds will be utilized for manufacturing, marketing, sales, and scaling supply chain operations for the January 2025 U.S. launch of the CONNEQT Pulse device. Shares issued will rank equally with existing shares, leveraging ASX Listing Rules 7.1 and 7.1A.
Joint Lead Managers Blackpeak Capital and Stralis Capital Partners will receive 6% of the raised amount. This strategic placement bolsters Cardiex’s mission to extend longevity through innovative medical technology solutions.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 21, 2025
Feb 20, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.